Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.66 |
| ▸ | CDK2 | P24941 | 20/20 | 0.66 |
| ▸ | CDK4 | P11802 | 19/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6594027 | 0.90 | CDK1 (0.70) | CDK1CDK2CDK4 | |
| SCHEMBL6595512 | 0.88 | CDK1 (0.65) | CDK1CDK2CDK4 | |
| SCHEMBL6595509 | 0.88 | CDK1 (0.65) | CDK1CDK2CDK4 | |
| SCHEMBL6596441 | 0.83 | CDK1 (0.81) | CDK1CDK2CDK4 | |
| SCHEMBL6595351 | 0.81 | CDK1 (0.73) | CDK1CDK2CDK4 | |
| SCHEMBL6599538 | 0.80 | CDK1 (0.73) | CDK1CDK2CDK4 | |
| SCHEMBL6595336 | 0.80 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6595545 | 0.79 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6598229 | 0.79 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6595360 | 0.78 | CDK1 (0.80) | CDK1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | claimed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | claimed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | claimed |
| EP-1280802-A4 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2003-06-11 | — | — | EP | claimed |
| EP-1280802-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | claimed |
| WO-2001085726-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2001-11-15 | — | — | WO | claimed |
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | disclosed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | CCNA1, CCNI, CCNT1 | CDK1 4/4885CDK2 13/4885CDK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.